The sector has seen billions in merger and acquisition activity in recent years; a September 2024 analysis by Insight ...

As the U.S. stock market faces heightened volatility amid escalating trade tensions and economic uncertainty, major indices like the Dow Jones and Nasdaq have entered correction and bear market ...

Lantheus Holdings, Inc. has a 12-month low of $58.46 and a 12-month high of $126.89. The stock has a market capitalization of $6.23 billion, a PE ratio of 15.13 and a beta of 0.38.

Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The company had revenue of $391.11 million for the quarter, compared to analyst estimates of $376.61 million.

Lantheus is promising up to $1.8 billion in milestone payments to POINT if the two radiotherapeutics get FDA approval and meet commercial objectives, plus royalties on net sales.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Lantheus has filed what it says is the first generic version of Novartis’ big-selling cancer radionuclide therapy Lutathera in the US, used to treat rare neuroendocrine tumours (NETs).

The transaction is expected to enhance Jabil’s development and commercial production of auto-injectors, pen injectors, inhalers, and on-body pumps. While FMS has specialized in the design, ...